WST Stock Fair Value – West Pharmaceutical Services’ Stock Underperforms on Monday in Comparison to Competitors
November 16, 2023
🌥️Trending News
West Pharmaceutical Services ($NYSE:WST) Inc. is a leading global provider of drug delivery and product protection solutions. On Monday, the company’s stock failed to keep up with its competitors, leaving it underperforming in comparison. Other stocks within the same industry surged, making West Pharmaceutical Services’ stock appear to be lagging behind. This lack of performance was surprising given the company’s history of success and potential for growth in the future. West Pharmaceutical Services is well known for its commitment to quality and innovation, providing customers with a range of products that are designed to optimize drug delivery and product protection.
This company has a wide customer base, with clients from diverse markets such as biopharmaceuticals, medical device, and diagnostics. West Pharmaceutical Services has also taken steps to strengthen its balance sheet and increase shareholder value. Though the company underperformed on Monday, investors remain hopeful that West Pharmaceutical Services will continue to show strength in the future and reach its full potential.
Price History
On Monday, West Pharmaceutical Services’ stock underperformed compared to its competitors. The company opened at $347.2 and closed at $347.5 on Tuesday, a 2.8% increase from its previous closing price of $338.1. Despite the slight increase, West Pharmaceutical Services’ stock still lagged behind its competitors who enjoyed a more significant surge on the market. This lackluster performance has caused investors to question the company’s future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for WST. More…
| Total Revenues | Net Income | Net Margin |
| 2.93k | 559.4 | 20.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for WST. More…
| Operations | Investing | Financing |
| 768.2 | -354.7 | -279.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for WST. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.75k | 886.5 | 38.76 |
Key Ratios Snapshot
Some of the financial key ratios for WST are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.8% | 22.9% | 22.8% |
| FCF Margin | ROE | ROA |
| 14.4% | 14.9% | 11.1% |
Analysis – WST Stock Fair Value
At GoodWhale, we recently conducted an analysis of WEST PHARMACEUTICAL SERVICES’s wellbeing. After an extensive analysis of the company’s financials and market trends, our proprietary Valuation Line has determined that the fair value of WEST PHARMACEUTICAL SERVICES share is $361.2. We believe this presents an exciting investment opportunity for those interested in WEST PHARMACEUTICAL SERVICES. More…
Peers
The company operates in North America, Europe, Asia, and South America. Seikagaku Corp, Shenyang Xingqi Pharmaceutical Co Ltd, and Shenzhen Salubris Pharmaceuticals Co Ltd are all competitors of West Pharmaceutical Services Inc.
– Seikagaku Corp ($TSE:4548)
Seikagaku Corp is a Japanese company that specializes in the research and development of pharmaceuticals. The company has a market cap of 53.35B as of 2022 and a return on equity of 2.38%. Seikagaku Corp’s products include treatments for osteoarthritis, inflammatory diseases, and cancer.
– Shenyang Xingqi Pharmaceutical Co Ltd ($SZSE:300573)
Shenyang Xingqi Pharmaceutical Co Ltd is a pharmaceutical company with a market cap of 10.63B as of 2022. The company has a return on equity of 12.24%. The company’s main products are traditional Chinese medicines and western medicines. The company also has a research and development center which is responsible for the development of new products and the improvement of existing products. The company has a strong marketing network and a good reputation in the industry.
– Shenzhen Salubris Pharmaceuticals Co Ltd ($SZSE:002294)
Shenzhen Salubris Pharmaceuticals Co Ltd is a Chinese pharmaceutical company with a market cap of 37.86B as of 2022. The company’s ROE is 6.05%. Shenzhen Salubris Pharmaceuticals Co Ltd is engaged in the research, development, manufacture and sale of pharmaceutical products. The company’s products include drugs for the treatment of cardiovascular and cerebrovascular diseases, cancer, infections, digestive diseases and other diseases.
Summary
West Pharmaceutical Services Inc. has seen a decline in its stock price on Monday compared to its competitors. This has raised concerns for investors as to what may have caused this decline. While the exact cause is uncertain, some possible factors could include the current macroeconomic climate, company-specific news, or changes in sentiment. Investors should take this into account when assessing whether to invest in West Pharmaceutical Services Inc.
Additionally, they should also consider their own risk tolerance and investment goals when making their decisions. Doing research into the company’s key performance metrics, financial statements, and industry trends may also be beneficial when determining whether to invest in West Pharmaceutical Services Inc.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
